Charles Landau, MD
Cardiovascular Disease · Trumbull, CTNPI 1639176597
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (42.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 70.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,569 and has fallen 78.6% since, to $335 in 2023.
Across 15 payments — averaging $147.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Bayer$325
- Amgen$122
- United Therapeutics Corporation$100
- Boston Scientific$89
- E.r. Squibb & Sons, L.L.C.$11
Across 49 payments — averaging $7641.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$282K
- AstraZeneca$45K
- Sanofi US Services Inc.$39K
- Merck$5K
- Eli Lilly$4K
What the payments were for
- Consulting fees$32515%
- Speaking & faculty fees$1005%
- Travel & lodging$93742%
- Food & beverage$85639%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 9 | $1,571 |
| Bayer | 2 | $325 |
| Amgen | 1 | $122 |
| United Therapeutics Corporation | 1 | $100 |
| Boston Scientific | 1 | $89 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,218 in reported general payments places this provider in the 60th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $38,921 |
| EliquisApixaban | 40 | $34,030 |
| XareltoRivaroxaban | 30 | $27,876 |
| OzempicSemaglutide | 20 | $22,616 |
| EntrestoSacubitril/Valsartan | 27 | $19,659 |
| FarxigaDapagliflozin Propanediol | 11 | $16,606 |
| Carvedilol ErCarvedilol Phosphate | 39 | $8,770 |
| Eplerenone | 25 | $1,681 |
| Clonidine | 18 | $1,074 |
| Metoprolol Succinate | 62 | $1,063 |
| Irbesartan | 39 | $997 |
| Carvedilol | 90 | $812 |
| Rosuvastatin Calcium | 97 | $698 |
| ClopidogrelClopidogrel Bisulfate | 45 | $430 |
| Amiodarone Hcl | 18 | $423 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Trumbull
- Manuel PunTrumbull$10K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.